| [1] 郑梅琴, 刘硕, 许瑞, 等. 国家组织药品集中采购对耐药结核病患者药物可负担性的影响[J]. 中国药业, 2022, 31(1):8-11. [2] 卢春容,房宏霞,陆普选,等. 2021 WHO全球结核病报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志,2021,6(4):368-372.
 [3] 聂理会, 初乃惠.《耐药结核病规划管理指南2011年更新版》解读[J]. 中国临床医生 2013, 41(3): 6-8.
 [4] 初乃惠. 积极推进耐药结核病全口服短程治疗方案的实施[J]. 中国临床医生杂志, 2020, 48(12):1387-1389.
 [5] 刘怡, 李燕芬, 沈晓君, 等. 抗结核药物使用引起患者肾功能损害的分析与护理[J]. 中国医药导报, 2014, 11(2):150-152.
 [6] WORLD HEALTH ORGANIZATION.WHO treatment guidelines for drug-resistant tuberculosis[R]. Geneva:World Health Organization, 2016.
 [7] BELLOMO R, RONCO C, KELLUM JA, et al.Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group[J]. Crit Care, 2004, 8(4): R204-212.
 [8] 中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10):1025-1073.
 [9] 王国杰. 耐多药肺结核患者抗结核药物不良反应分析[J]. 现代医药卫生, 2019, 35(24):3821-3823.
 [10] WORLD HEALTH ORGANIZATION.Companion handbook to the WHO guidelines for the programmatic management of drug¬resistant tuberculosis[R]. Geneva: World Health Organization, 2014.
 [11] WORLD HEALTH ORGANIZATION.WHO treatment guidelines for multidrugand rifampicin-resistant tuberculosis[R].Geneva: World Health Organization, 2018.
 [12] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on drug-resistant tuberculosis treatment.Geneva: World Health Organization, 2019.
 [13] 周文强, 初乃惠. 耐药结核病治疗的进展[J].中国临床医生杂志, 2020, 48(12):1396-1399.
 [14] 刘群群, 苗艳芳. 耐多药肺结核88例抗结核药物不良反应发生情况分析[J]. 中国药物与临床, 2015, 15(5):730-732.
 [15] 王玉洲. 抗结核药致肾功能损害发生机制及防治对策[C], 全国抗结核治疗的不良反应及处理学术会议论文汇编, 2001.
 [16] 杨梁梓,任坦坦,傅向东,等.含贝达喹啉新方案治疗耐药肺结核的疗效与安全性研究[J/CD].新发传染病电子杂志,2021,6(4):302-305.
 [17] WU H, HUANG J.Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies[J]. Curr Drug Metab, 2018, 19(7): 559-567.
 [18] WORLD HEALTH ORGANIZATION.Multidrug and extensively drug-resistant TB(M/XDR-TB)-2010 global report on surveillance and response[R].Geneva: World Health Organization, 2010.
 [19] AHMAD N, JAVAID A, SYED SULAIMAN SA, et al.Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients[J]. Am J Ther, 2018, 25(5): e533-e540.
 [20] SHIBESHI W, SHETH AN, ADMASU A, et al.Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study[J]. BMC Pharmacol Toxicol, 2019, 20(1):20-31.
 [21] 陈心春,温志华.基于宿主基因定向治疗耐多药结核病:机遇与挑战[J/CD].新发传染病电子杂志, 2017, 2(3):129-132.
 |